18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
20:14 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Dec. 14 to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab...
00:06 , Dec 15, 2018 |  BC Extra  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
19:26 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius to move forward with Hong Kong listing

Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said on Sept. 27 its board approved a resolution to list Shanghai Henlius Biotech Inc. (Shanghai, China) on the Hong Kong stock exchange. Shanghai Henlius, a JV...
22:47 , Apr 24, 2018 |  BC Extra  |  Company News

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig." This quarter,...
21:16 , Apr 24, 2018 |  BC Extra  |  Company News

Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its...
14:50 , Apr 6, 2018 |  BC Week In Review  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...